AstraZeneca 3Q10 3Q Revenues: $7.9 billion (-4%) 3Q Earnings: $1.8 billion (-23%) YTD Revenues: $24.7 billion (+3%) YTD Earnings: $6.2 billion (-1%) Comments: Generic competition in the U.S. for Arimidex, Pulmicort Respules and Toprol-XL, along with a lack of H1N1 pandemic vaccine revenue, led U.S. sales to drop 13% in 3Q10 to $3.2 billion. U.S. sales are down 5% YTD to $10.3 billion. Western Europe sales are up 3% and 4% for the quarter and YTD respectively, to $2.1 billion and $...